These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2976254)

  • 21. Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride.
    Hall H; Farde L; Sedvall G
    J Neural Transm; 1988; 73(1):7-21. PubMed ID: 2969950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain.
    Andersen PH
    Eur J Pharmacol; 1988 Jan; 146(1):113-20. PubMed ID: 2895008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes.
    Ferre S; von Euler G; Johansson B; Fredholm BB; Fuxe K
    Proc Natl Acad Sci U S A; 1991 Aug; 88(16):7238-41. PubMed ID: 1678519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. D2- but not D3-dopamine receptors detected in the anterior pituitary.
    Titeler M; Van Loon GR; Seeman P; Brown GM
    Eur J Pharmacol; 1981 Apr; 71(1):143-6. PubMed ID: 7238583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific binding of 3H-SCH 23390 to dopamine D1 receptors in vivo.
    Andersen PH; Grønvald FC
    Life Sci; 1986 Apr; 38(16):1507-14. PubMed ID: 2871467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preferential inhibition of ligand binding to calf striatal dopamine D1 receptors by SCH 23390.
    Cross AJ; Mashal RD; Johnson JA; Owen F
    Neuropharmacology; 1983 Nov; 22(11):1327-9. PubMed ID: 6141534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo labelling of pituitary dopamine D-2 receptors in the male rat using [3H]-raclopride.
    Köhler C; Karlsson-Boethius G
    J Neural Transm; 1989; 76(1):13-28. PubMed ID: 2523467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET.
    Rosa-Neto P; Doudet DJ; Cumming P
    Neuroimage; 2004 Jul; 22(3):1076-83. PubMed ID: 15219579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
    Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
    J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression.
    Sumiyoshi T; Stockmeier CA; Overholser JC; Thompson PA; Meltzer HY
    Brain Res; 1995 May; 681(1-2):109-16. PubMed ID: 7552267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors.
    Subramaniam S; Lucki I; McGonigle P
    Brain Res; 1992 Feb; 571(2):313-22. PubMed ID: 1351781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of flunarizine with dopamine D2 and D1 receptors.
    Ambrosio C; Stefanini E
    Eur J Pharmacol; 1991 May; 197(2-3):221-3. PubMed ID: 1833208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. D1 and D2 specific dopamine antagonist modulate the caudate nucleus neuronal responses to chronic methylphenidate exposure.
    Venkataraman S; Claussen C; Dafny N
    J Neural Transm (Vienna); 2017 Feb; 124(2):159-170. PubMed ID: 27853928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A post-mortem study on striatal dopamine receptors in Parkinson's disease.
    Rinne JO; Laihinen A; Lönnberg P; Marjamäki P; Rinne UK
    Brain Res; 1991 Aug; 556(1):117-22. PubMed ID: 1834312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoradiographic localization of D1 and D2 dopamine receptors in the human brain.
    De Keyser J; Claeys A; De Backer JP; Ebinger G; Roels F; Vauquelin G
    Neurosci Lett; 1988 Aug; 91(2):142-7. PubMed ID: 2972942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential modulation of dopamine D1-receptor binding and mRNA expression in the basal ganglia by the D1-receptor antagonist, SCH-23390.
    Yu J; Coirini H; Källström L; Wiesel FA; Johnson AE
    Synapse; 1998 Sep; 30(1):38-48. PubMed ID: 9704879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O; Biggio G
    Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo autoradiography of [3H]SCH 39166 in rat brain: selective displacement by D1/D5 antagonists.
    Duffy RA; Hunt MA; Wamsley JK; McQuade RD
    J Chem Neuroanat; 2000 May; 19(1):41-6. PubMed ID: 10882836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of dopamine binding sites in the rat superior cervical ganglion and caudate nucleus.
    Ariano MA
    Brain Res; 1987 Sep; 421(1-2):245-54. PubMed ID: 2961410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.